Literature DB >> 14578010

The pharmacology of psilocybin.

Torsten Passie1, Juergen Seifert, Udo Schneider, Hinderk M Emrich.   

Abstract

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide. These mushrooms represent a growing problem regarding hallucinogenic drug abuse. Despite its experimental medical use in the 1960s, only very few pharmacological data about psilocybin were known until recently. Because of its still growing capacity for abuse and the widely dispersed data this review presents all the available pharmacological data about psilocybin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14578010     DOI: 10.1080/1355621021000005937

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  64 in total

1.  Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.

Authors:  Boris B Quednow; Michael Kometer; Mark A Geyer; Franz X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Development of a psilocin immunoassay for serum and blood samples.

Authors:  C Albers; H Köhler; M Lehr; B Brinkmann; J Beike
Journal:  Int J Legal Med       Date:  2004-08-03       Impact factor: 2.686

Review 3.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

4.  The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.

Authors:  Alan K Davis; Joseph P Barsuglia; Rafael Lancelotta; Robert M Grant; Elise Renn
Journal:  J Psychopharmacol       Date:  2018-04-30       Impact factor: 4.153

Review 5.  Human hallucinogen research: guidelines for safety.

Authors:  Mw Johnson; Wa Richards; Rr Griffiths
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

6.  Clinical potential of psilocybin as a treatment for mental health conditions.

Authors:  Jeremy Daniel; Margaret Haberman
Journal:  Ment Health Clin       Date:  2018-03-23

Review 7.  Alternative drugs of abuse.

Authors:  M E Sutter; J Chenoweth; T E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

Review 8.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

9.  Novel, unifying mechanism for mescaline in the central nervous system: electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2009 Sep-Oct       Impact factor: 6.543

10.  Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.

Authors:  Theresa M Carbonaro; Matthew W Johnson; Ethan Hurwitz; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2017-11-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.